Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Mar 29;113(3):542–551. doi: 10.1016/j.ijrobp.2022.03.007

Figure 2.

Figure 2.

Five-year local-regional recurrence for patients enrolled on NSABP B-40, and B-41 stratified by clinical node involvement and subsequent response to neoadjuvant chemotherapy. (A) B-40; (B) B-41; (C) HR+ patients from B40; and (D) TN patients from B40. 95% Confidence Intervals are provided in Supplementary Tables 10 and 11. Abbreviations: HR+ = Hormone-receptor positive; TN = triple negative